证券代码：002932 证券简称：明德生物 公告编号：2025-033 武汉明德生物科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日 召开第四届董事会第十九次会议、第四届监事会第十六次会议，2025 年 5 月 16 日召开 2024 年年度股东大会审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意公司使用不超过 23,000.00 万元（含）的闲置募集资金投资 安全性高、流动性好、保本型的理财产品或定期存款、结构性存款，在上述额度 内，资金可在公司股东大会审议通过之日起 12 个月内滚动使用。董事会授权总 经理行使该项投资决策权并由财务负责人负责具体购买事宜。具体内容详见公司 于 2025 年 4 月 25 日在巨潮资讯网披露的《关于使用部分闲置募集资金进行现金 管理的公告》（公告编号：2025-021）。 集资金进行现金管理购买理财产品的结算，不会用于存放非募集资金或用作其他 用途。 二、投资风险 ...

证券代码：002932 证券简称：明德生物 公告编号：2025-032 武汉明德生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）本次实施的利润 分配方案按公司现有总股本 232,520,957 减去公司回购专户中持有的股份数量 13,034,741 股为基数，向全体股东每 10 股派发现金红利 12.00 元（含税），不送 红股，不以公积金转增股本。 2、因公司回购股份不参与分红，本次权益分派实施后，根据股票市值不变 原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比 例将减少。因此，本次权益分派实施后除权除息价格计算时，每股现金红利（含 税）应以1.1327299元/股计算（每股现金红利=现金分红总额/总股本，即1.1327299 元/股=263,383,459.20 元÷232,520,957 股）（结果取小数点后七位，最后一位直 接截取，不四舍五入），按公司总股本（含回购股份）折算每 10 股现金分红金 额（含税）为 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and industry comparison [1][2] - As of June 3, the closing price of Mingde Biological was 19.71 yuan, with a PE ratio of 118.10, marking a new low in 111 days, and a total market capitalization of 4.583 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of April 18, 2025, the number of shareholders for Mingde Biological was 25,248, a decrease of 345 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of the company includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, representing a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]

证券代码：002932 证券简称：明德生物 公告编号：2025-031 武汉明德生物科技股份有限公司 对外投资进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、进展情况说明 基于发展战略调整，经全体合伙人协商一致，全体合伙人同比例减少认缴出 资额。近日公司收到青柠基金完成工商变更登记通知，认缴出资额由 12,000 万 元人民币变更为 9,960 万元人民币，其中，公司认缴出资额由 2,450 万元人民币 减少为 2,033.50 万元人民币。合伙人认缴出资变更情况如下： | 合伙人名称 | 变更前认缴出 | 变更前出资 | 变更后认缴出 | 变更后出 | | --- | --- | --- | --- | --- | | | 资额（万元） | 比例 | 资额（万元） | 资比例 | | 武汉明德生物科技股份有限公司 | 2,450 | 20.42% | 2,033.50 | 20.42% | | 湖北长创产业投资基金有限公司 | 2,450 | 20.42% | 2,033.50 | 20.42% | | --- | --- | --- | -- ...

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company was 16.37% [1] Market Position - The company's current stock price is 18.75 yuan, with a decline of 1.16% [1] - The rolling price-to-earnings (PE) ratio is 112.35, significantly higher than the industry average of 48.92 and the industry median of 35.68, placing the company at the 108th position in the industry ranking [1][2] - The total market capitalization of the company is 4.36 billion yuan [1] Institutional Holdings - As of the first quarter of 2025, six institutions hold shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.84 million shares valued at 250 million yuan [1]

Group 1 - The core viewpoint of the articles indicates that Mingde Biological's stock is currently underperforming with a closing price of 19.0 yuan, down 1.91%, and a rolling PE ratio of 113.85 times, significantly higher than the industry average [1][2] - The total market capitalization of Mingde Biological is reported at 4.418 billion yuan, ranking 108th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 4.511 million yuan in major funds on May 22, with a total outflow of 11.4719 million yuan over the past five days, indicating a negative trend in investor sentiment [1] Group 2 - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as providing information solutions for critical care and third-party medical testing services [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, but reported a net loss of approximately 3.662988 million yuan, a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]

证券代码：002932 证券简称：明德生物 公告编号：2025-030 武汉明德生物科技股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 2、本次股东大会未变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 3、会议召开方式： 本次股东大会采取现场投票、网络投票相结合的方式召开。 （1）现场投票：股东本人出席现场会议或者通过授权委托书委托他人出席 现场会议； （1）现场会议：2025年5月16日（星期五）14:00开始 （2）网络投票时间：2025年5月16日 其中通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月 16日（星期五）上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为：2025年5月16日（星期五）9:15-15:00期间 的任意时间。 2、现场会议召开地点：武汉市东湖新技术开发区九龙中路77号武汉明德生 物科技产业园1 ...

北 京 大 成 （ 武 汉 ） 律 师 事 务 所 关 于 武 汉 明 德 生 物 科 技 股 份 有 限 公 司 2024 年 年 度 股 东 大 会 的 法 律 意 见 书 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范性文 件的要求，北京大成（武汉）律师事务所（以下简称"本所"）接受武汉明德生物 科技股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2024 年年度 股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序及表决结果发表法律意见，并不对本次股东大会所审 议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法律意见书随 本次股东大会其他信息披露资料一并公告。 北 京 大 成 （ 武 汉 ） 律 师 事 务 所 www.dentons.cn 武汉市江岸区建设大道 718 号浙商大厦 10 层（430015） 10/F, Zheshang ...

Company Overview - Mingde Biological Technology Co., Ltd. primarily engages in the research, development, production, sales, and service of in vitro diagnostic reagents and diagnostic instruments [1] - The company's main products and services cover three major areas: in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of Q1 2025, the company reported operating revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, reflecting a year-on-year decline of 111.43% [1] - The gross profit margin stood at 16.37% [1] Market Position - The company's closing stock price on May 7 was 18.72 yuan, down 1.58%, with a rolling price-to-earnings (PE) ratio of 112.17 times [1] - The total market capitalization is 4.353 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 49.02 times, with a median of 36.25 times, placing Mingde Biological at the 107th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders was 25,981, a decrease of 717 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Industry Recognition - In December 2022, a hospital in Hubei Province utilizing the company's information solutions won the Best Solution Award for Smart Chest Pain Center at the China Cardiovascular Health Conference, marking it as the only county-level hospital to receive this award [1]

前十大流通股东累计持有： 4471.1万股，累计占流通股比： 28.64%，较上期变化： 83.49万股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 陈莉莉 | 1572.97 | 10.08 | 不变 | | 王颖 | 897.92 | 5.75 | 不变 | | 陈鑫涛 | 429.63 | 2.75 | -16.00 | | 广发价值核心混合A | 284.62 | 1.82 | 不变 | | 中国平安人寿保险股份有限公司-分红-个险分红 | 265.16 | 1.70 | 新进 | | 易方达中证红利ETF | 240.56 | 1.54 | 15.83 | | 中国平安人寿保险股份有限公司-自有资金 | 219.53 | 1.41 | -0.56 | | 招商中证红利ETF | 194.69 | 1.25 | 29.49 | | 周琴 | 186.02 | 1.19 | -2.05 | | 融通健康产业灵活配置混合A/B | 180.00 | 1.15 | -83.28 | | 较上个报告期退出前十大股东 ...